Antibodies and related molecules that bind to 161P2F10B proteins

US7427399B2 · kind B2 · utility

Assignee

• Latency, LLC · US

Inventors

• Aya Jakobovits · Beverly Hills, US
• Steven B. Kanner · Berkeley, US
• Pia M. Challita-Eid · Calabasas, US
• Juan J. Perez-Villar · Mercerville, US
• Daulet Satpaev · Santa Monica, US
• Arthur B. Raitano · Los Angeles, US
• Robert Kendall Morrison · Santa Monica, US
• Karen Jane Meyrick Morrison · Santa Monica, US
• Xiao-Chi Jia · Los Angeles, US
• Jean Gudas · Los Angeles, US

Key dates

• Filing date: Mar 31, 2006
• Grant date: Sep 23, 2008
• Expiry date: Mar 31, 2026

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.